Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.34 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.34 |
| ▸ | CPT2 | P23786 | 1/20 | 0.32 |
| ▸ | CPT1A | P50416 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2399402 | 0.97 | TSHR (0.42) | TSHRALDH1A1LMNAAPEX1BBOX1 | |
| Acetic Acid SCHEMBL9389970 | 0.91 | TSHR (0.42) | TSHRALDH1A1LMNAAPEX1BBOX1 | |
| Acrylamide SCHEMBL17457007 | 0.84 | TSHR (0.41) | TSHRALDH1A1LMNAAPEX1BBOX1 | |
| SCHEMBL15327604 | 0.79 | TSHR (0.43) | TSHRALDH1A1LMNAAPEX1BBOX1 | |
| SCHEMBL29254396 | 0.78 | BBOX1 (0.42) | BBOX1 | |
| SCHEMBL1898329 | 0.76 | TSHR (0.52) | TSHRALDH1A1LMNAAPEX1 | |
| SCHEMBL1974755 | 0.75 | ACHE (0.39) | TSHRLMNABBOX1SLC22A16 | |
| Bromide SCHEMBL22034719 | 0.74 | TSHR (0.50) | TSHRALDH1A1LMNAAPEX1 | |
| SCHEMBL8742965 | 0.74 | TSHR (0.43) | TSHRALDH1A1LMNAAPEX1 | |
| Hydrochloric Acid SCHEMBL8616930 | 0.74 | ALDH1A1 (0.55) | TSHRALDH1A1LMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3003277-B1 | PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION COMPRISING RIVAROXABAN | SANDOZ AG (CH) | 2019-02-20 | — | — | EP | claimed |
| EP-1588692-B1 | Durable foamed composition | WELLA AG (DE) | 2008-09-24 | — | — | EP | claimed |
| US-20250136682-A1 | ANTI-SIGLEC-3 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | ACADEMIA SINICA (TW) | 2025-05-01 | — | — | US | disclosed |
| EP-4504263-A1 | ANTI-SIGLEC-3 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | Academia Sinica (TW) | 2025-02-12 | — | — | EP | disclosed |
| EP-4456983-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MACITENTAN AS ACTIVE INGREDIENT AND OTHER RELEVANT EXCIPIENTS | Humanis Saglik Anonim Sirketi (TR) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023196761-A1 | ANTI-SIGLEC-3 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | ACADEMIA SINICA (TW) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023128898-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MACITENTAN AS ACTIVE INGREDIENT AND OTHER RELEVANT EXCIPIENTS | HUMANIS SAGLIK ANONIM SIRKETI (TR) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023112049-A1 | HERBAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF LIVER DISORDERS | DR. REDDY’S LABORATORIES LIMITED (IN) | 2023-06-22 | — | — | WO | disclosed |
| EP-2806860-B1 | PHARMACEUTICAL COMPOSITION CONTAINING CRYSTALLINE SORAFENIB TOSYLATE | SANDOZ AG (CH) | 2023-04-19 | — | — | EP | disclosed |
| EP-3601278-B1 | CRYSTALLINE FORM OF MASITINIB | SANDOZ AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022070209-A1 | BIPHASIC RELEASE FIXED DOSE COMBINATION FORMULATIONS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2022-04-07 | — | — | WO | disclosed |
| EP-1868579-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREA FOR THE TREATMENT OF CANCER | BAYER SCHERING PHARMA AG (DE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2094268-A2 | DRUG COMBINATIONS WITH SUBSTITUTED DIARYL UREAS FOR THE TREATMENT OF CANCER | Bayer HealthCare, LLC (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20080242707-A1 | Using 4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)-2-pyridinecarboxylic acid methyl amide | BAYER HEALTHCARE AG (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20080045589-A1 | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer | BAYER HEALTHCARE LLC | 2008-02-21 | — | — | US | disclosed |
| EP-1868579-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREA FOR THE TREATMENT OF CANCER | Bayer HealthCare AG (DE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007139930-A2 | DRUG COMBINATIONS WITH SUBSTITUTED DIARYL UREAS FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE LLC (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2006094626-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN OMEGA- CARBOXYARYL SUBSTITUTED DIPHENYL UREA FOR THE TREATMENT OF CANCER | BAYER HEALTHCARE AG (DE) | 2006-09-14 | — | — | WO | disclosed |
| US-6024987-A | ANTACIDS AND H2 ANTAGONIST WITH DISINTEGRANT | RHONE-POULENC RORER GMBH (DE) | 2000-02-15 | — | — | US | disclosed |
| US-6008249-A | COMPRISING A PROMOTER FOR ACCELERATING THE DECOMPOSITION OF DRUG MIXTURE IN THE MOUTH OR IN A LIQUID | RHONE-POULENC RORER GMBH (DE) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045589-A1 | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer | XPOT, XPO6, DDB1 | TSHR 4549/4885ALDH1A1 2861/4885LMNA 3298/4885 |
| US-20080242707-A1 | Using 4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)-2-pyridinecarboxylic acid methyl amide | MKI67, CCNC, CCNI | TSHR 4435/4885ALDH1A1 1329/4885LMNA 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.